Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial

Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial

Several lines of emerging data point to an imbalance between neuronal excitation and inhibition in at least a subgroup of individuals with autism spectrum disorder (ASD), including in those with fragile X syndrome (FXS), one of the most common genetic syndromes within ASD. In animal models of FXS an...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Veenstra-VanderWeele, Jeremy, Cook, Edwin H, King, Bryan H, Zarevics, Peter, Cherubini, Maryann, Walton-Bowen, Karen, Bear, Mark, Wang, Paul P, Carpenter, Randall L
Beste egile batzuk: Picower Institute for Learning and Memory
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Springer Science and Business Media LLC 2020
Sarrera elektronikoa:https://hdl.handle.net/1721.1/126510

Internet

https://hdl.handle.net/1721.1/126510

Antzeko izenburuak